Application/Control Number: 10/088,780

Art Unit: 0

CLMPTO

03/20/2002

to that agent.

ER

1. (Amended) A composition for protection of an animal against a disease-causing agent, the composition comprising a non-infectious nucleic acid construct encoding a recombinant antibody

- (Amended) A composition according to claim 1 wherein the animal is selected from a mammal or a fish.
 - (Amended) A composition according to claim 1 wherein the animal has a deficient immune system.
 - (Amended) A composition according to claim 1 wherein the disease-causing agent is selected from a pathogen, an allergen or a toxic substance.
 - (Amended) A composition according to claim 1 wherein the protection is prophylactic.

- (Amended) A composition according to claim 1 wherein the encoded recombinant antibody is derived from an antibody raised against the disease-causing agent.
- 7. (Amended) A composition according to claim 1 wherein the encoded antibody molecule comprises variable domains of immunoglobulin Heavy and Light chain genes linked together by a linker sequence.
- (Amended) A composition according to claim 1, wherein the nucleic acid construct further comprises a gene sequence encoding a secretion signal peptide.
- (Amended) A composition according to claim 1 comprising genes encoding antibody molecules to several different epitopes of the disease-causing agent.
- (Amended) A composition according to claim 1 comprising a gene-expression library encoding antibodies to the diseasecausing agent.
- (Amended) A composition according to claim 10 wherein the gene expression library encodes single-chain antibody molecules to the disease-causing agent.
- (Amended) A composition according to claim 1 wherein the encoded recombinant antibody is a virus-neutralising antibody.
- (Amended) A composition according to claim 12 wherein the encoded virus-neutralising antibody is single chain molecule.

- 14. (Amended) A composition according to claim 1 including a nucleic acid construct encoding a viral haemorrhagic septicaemia virus VHSV-neutralising monoclonal antibody 3F1H10 with two amino acids substituents in the H-chain gene respectively Asn 35a to Thr and Lys 64 to Thr and with the secretion signal of rainbow trout transforming growth factor (TGF-beta) added to the 5' end of the gene.
 - 15. (Amended) A composition according to claim 6 wherein when the disease-causing agent is an allergen the antibody molecule is derived from an antibody raised against IgE molecules.
 - 16. (Amended) A composition according to claim 1 wherein the nucleic acid construct is formed from DNA.
 - 17. (Amended) A composition according to claim 1 wherein the composition is in the form of a vaccine, dosage form, cream, ointment, liquid or paint.
 - 18. (Amended) A composition according to claim 17 wherein the composition is for delivery by injection, spray or gene gun.

- -- 21. A composition for protection of an animal against a disease-causing agent, the composition comprising a non-infectious nucleic acid construct encoding a recombinant antibody to that agent wherein the encoded antibody molecule comprises variable domains of immunoglobulin Heavy and Light chain genes linked together by a linker sequence.
 - A composition according to claim 21 wherein the animal is selected from a mammal or a fish.
 - A composition according to claim 21 wherein the animal has a deficient immune system.
 - 24. A composition according to claim 21 wherein the diseasecausing agent is selected from a pathogen, an allergen or a toxic substance.
 - 25. A composition according to claim 21 wherein the protection is prophylactic.
- 26. A composition according to claim 21 wherein the encoded recombinant antibody is derived from an antibody raised against the disease-causing agent.

- 27. A composition according to claim 21, wherein the nucleic acid construct further comprises a gene sequence encoding a secretion signal peptide.
- 28. A composition according to claim 21 comprising genes encoding antibody molecules to several different epitopes of the disease-causing agent.
- 29. A composition according to claim 21 comprising a geneexpression library encoding antibodies to the disease-causing agent.
- 30. A composition according to claim 29 wherein the gene expression library encodes single-chain antibody molecules to the disease-causing agent.
- 31. A composition according to claim 21 wherein the encoded recombinant antibody is a virus-neutralising antibody.
- 32. A composition according to claim 31 wherein the encoded virus-neutralising antibody is single chain molecule.
- 33. A composition according to claim 21 including a nucleic acid construct encoding a viral haemorrhagic septicaemia virus VHSV-neutralising monoclonal antibody 3F1H10 with two amino acids substituents in the H-chain gene respectively Asn 35a to Thr and Lys 64 to Thr and with the secretion signal of rainbow trout transforming growth factor (TGF-beta) added to the 5' end of the gene.

- 34. A composition according to claim 26 wherein when the disease-causing agent is an allergen the antibody molecule is derived from an antibody raised against IgE molecules.
- 35. A composition according to claim 21 wherein the nucleic acid construct is formed from DNA.
- 36. A composition according to claim 21 wherein the composition is in the form of a vaccine, dosage form, cream, ointment, liquid or paint.
- 37. A composition according to claim 36 wherein the composition is for delivery by injection, spray or gene gun.

- 38. A composition for protection of a fish against a diseasecausing agent, the composition comprising a non-infectious DNA
 construct encoding a viral haemorrhagic septicaemia virus VHSVneutralising monoclonal antibody 3F1H10 with two amino acids
 substituents in the H-chain gene respectively Asn 35a to Thr and
 Lys 64 to Thr and with the secretion signal of rainbow trout
 transforming growth factor (TGF-beta) added to the 5' end of the
 gene.
- 39. A composition according to claim 38 wherein the protection is prophylactic.
- 40. A composition according to claim 38 wherein the encoded antibody molecule comprises variable domains of immunoglobulin Heavy and Light chain genes linked together by a linker sequence.
- 41. A composition according to claim 38, wherein the nucleic acid construct further comprises a gene sequence encoding a secretion signal peptide.
- 42. A composition according to claim 38 wherein the composition is in the form of a vaccine, dosage form, cream, ointment, liquid or paint.
- 43. A composition according to claim 38 wherein the composition is for delivery by injection, spray or gene gun.

- 44. A method of treating an animal comprising administering thereto a composition according to claim 1.
- 45. A method according to claim 44, wherein said composition mediates expression of a recombinant antibody to the pathogen, allergen or toxin.
- 46. A method of treating an animal comprising administering thereto a composition according to claim 3.
- 47. A method of treating an animal comprising administering thereto a composition according to claim 6.
- 48. A method of treating an animal comprising administering thereto a composition according to claim 21.
 - 49. A method of treating a fish comprising administering
- 50. A method of treating an animal with a congenital or acquired imunodefficiency, comprising administration of a number of non-infectious nucleic acid constructs encoding antibodies against a spectrum of disease-causing agents.
- 51. A method according to claim 44, wherein said animal is a fish or another aquatic animal.
- 52. A method according to claims 44, wherein said animal is a memmal.
- 53. A method according to claim 52, wherein said mammal is a human.
- 54. A method according to claim 50, wherein said animal is a human. --